Eli Lilly's Weight-Loss and Diabetes Drugs Contribute Over Two-Thirds of Q1 Revenue
In the first quarter of 2026, Eli Lilly reported that its weight-loss drug Zepbound and diabetes treatment Mounjaro generated $12.8 billion in combined revenue, accounting for nearly two-thirds of the company's total sales during the period.
Tickers: $LLY
Topics: Eli Lilly financial performance Mounjaro pharmaceuticals Zepbound